Scott A Rollins

US Patent:

6355245, Mar 12, 2002

Filed:

Jun 7, 1995

Appl. No.:

08/487283

Inventors:

Mark J. Evans - Cheshire CT
Louis A. Matis - Southport CT
Eileen Elliott Mueller - East Haven CT
Steven H. Nye - Mequon WI
Scott Rollins - Monroe CT
Russell P. Rother - Cheshire CT
Jeremy P. Springhorn - Cheshire CT
Stephen P. Squinto - Bethany CT
Thomas C. Thomas - Madison CT
James A. Wilkins - Woodbridge CT

Assignee:

Alexion Pharmaceuticals, Inc. - Cheshire CT

International Classification:

A61K 39395

US Classification:

4241451, 4241301, 4241331, 4241351, 4241411, 4241581, 4241391, 424130, 5303871, 5303873, 5303879, 5303881, 53038823, 53038825, 5303887, 435326, 435328, 435331, 435 33 L, 435337, 435343, 435346

Abstract:

The use of anti-C5 antibodies, e. g. , monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.

US Patent:

6916654, Jul 12, 2005

Filed:

May 5, 2000

Appl. No.:

09/566254

Inventors:

Peter J. Sims - Mequon WI, US
Alfred L. M. Bothwell - Guilford CT, US
Eileen A. Elliot - New Haven CT, US
Richard A. Flavell - Killingworth CT, US
Joseph Madri - North Branford CT, US
Scott Rollins - Monroe CT, US
Leonard Bell - Woodbridge CT, US
Stephen Squinto - Irvington NY, US

Assignee:

Oklahoma Medical Research Foundation - Oklahoma City OK
Yale University - New Haven CT

International Classification:

C12N005/10
C12N015/63
A61K048/00
A01N067/027

US Classification:

435325, 4353201, 435455, 800 8, 800 13, 800 18, 514 44

Abstract:

Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i. e. , hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.

US Patent:

7833530, Nov 16, 2010

Filed:

May 15, 2009

Appl. No.:

12/467060

Inventors:

Richard Alvarez - Edmond OK, US
Scott Rollins - Oklahoma City OK, US

Assignee:

Selexys Pharmaceuticals Corporation - Oklahoma City OK

International Classification:

A61K 39/395
C07K 16/28

US Classification:

4241541, 4241301, 4241331, 4241411, 4241431, 4241441, 4241521, 4241531, 4241721, 4241731, 5303871, 5303873, 5303881, 5303882, 53038822, 5303887, 53038873, 53038875

Abstract:

The present invention is directed to antibodies and binding fragments thereof, which bind with high affinity and specificity to human P-selectin glycoprotein ligand 1 (PSGL-1) and which block both selectin and chemokine binding to PSGL-1 expressed on leukocytes, lymphocytes and endothelial cells and thus which inhibit migration and/or rolling of these cells and to methods for screening for such antibodies and binding fragments thereof and to methods of therapeutic use thereof.

US Patent:

20020045247, Apr 18, 2002

Filed:

May 8, 1997

Appl. No.:

08/776161

Inventors:

RUSSELL P. ROTHER - CHESHIRE CT, US
SCOTT A. ROLLINS - OXFORD CT, US
WILLIAM L. FODOR - MADISON CT, US
JEREMY P. SPRINGHORN - GUILFORD CT, US
STEPHEN P. SQUINTO - BETHANY CT, US

International Classification:

C12N015/09
C12N015/00
C12N015/63
C12N015/70
C12N015/74

US Classification:

435/320100

Abstract:

Methods and compositions are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The reduction of levels of galactose alpha (1,3) galactosyl epitopes on the retroviral vector particles and/or the blockade of antibody binding to such epitopes have been found to render the particles less sensitive to inactivation by complement mediated mechanisms, and to thus allow transduction in the presence of complement containing body fluids. Means are provided for obtaining such reductions.

US Patent:

20110081666, Apr 7, 2011

Filed:

Nov 15, 2010

Appl. No.:

12/946372

Inventors:

RICHARD ALVAREZ - EDMOND OK, US
SCOTT ROLLINS - OKLAHOMA CITY OK, US

International Classification:

G01N 33/53

US Classification:

435 724, 436501, 435 722

Abstract:

The present invention is directed to antibodies and binding fragments thereof, which bind with high affinity and specificity to human P-selectin glycoprotein ligand 1 (PSGL-1) and which block both selectin and chemokine binding to PSGL-1 expressed on leukocytes, lymphocytes and endothelial cells and thus which inhibit migration and/or rolling of these cells and to methods for screening for inhibitory compounds including such antibodies and binding fragments thereof and to methods of therapeutic use thereof.

US Patent:

20110212096, Sep 1, 2011

Filed:

Dec 21, 2010

Appl. No.:

12/974539

Inventors:

Scott Rollins - Oklahoma City OK, US
Richard Alvarez - Edmond OK, US
Russell Rother - Oklahoma City OK, US
Rodger P. McEver - OKlahoma City OK, US
Ziad S. Kawar - Oklahoma City OK, US

International Classification:

A61K 39/395
C07K 16/28
C07K 16/46
C07H 21/04
C12N 1/00
C12N 5/00
A61P 29/00
A61P 17/06
A61P 35/00
A61P 7/02
A61P 11/06
A61P 9/10

US Classification:

4241391, 5303879, 5303873, 536 2353, 435243, 435325

Abstract:

Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.

US Patent:

20110287017, Nov 24, 2011

Filed:

Aug 5, 2011

Appl. No.:

13/204508

Inventors:

Scott Rollins - Oklahoma City OK, US
Richard Alvarez - Edmond OK, US
Russell Rother - Oklahoma City OK, US
Rodger P. McEver - Oklahoma City OK, US
Ziad S. Kawar - Oklahoma City OK, US

International Classification:

A61K 39/395
A61P 37/06
A61P 11/06
A61P 29/00
A61P 17/06

US Classification:

4241391

Abstract:

Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.

US Patent:

20110293617, Dec 1, 2011

Filed:

Dec 21, 2010

Appl. No.:

12/974739

Inventors:

Scott Rollins - Oklahoma City OK, US
Richard Alvarez - Edmond OK, US
Russell Rother - Oklahoma City OK, US
Rodger P. McEver - Oklahoma City OK, US
Ziad S. Kawar - Oklahoma City OK, US

International Classification:

A61K 39/395
C07H 21/04
A61P 7/00
C12N 1/19
C12N 1/15
C07K 16/28
C12N 5/10

US Classification:

4241391, 5303879, 5303873, 536 2353, 435331, 43525421, 4352544, 4352543

Abstract:

Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.